Brief: Axsome Therapeutics Announces Settlement Resolving All Sunosi® (Solriamfetol) Patent Litigation
03/06/2026 12:04
BRIEF-Axsome Therapeutics Announces Settlement Resolving All Sunosi® (Solriamfetol) Patent Litigation June 3 (Reuters) - Axsome Therapeutics Inc AXSM.O:
AXSOME THERAPEUTICS ANNOUNCES SETTLEMENT RESOLVING ALL SUNOSI® (SOLRIAMFETOL) PATENT LITIGATION
AXSOME THERAPEUTICS - RESOLVES ALL PATENT LITIGATION RELATED TO SUNOSI
AXSOME THERAPEUTICS - FIVE COMPANIES GRANTED RIGHT TO SELL GENERIC SUNOSI FROM 2040, SUBJECT TO FDA APPROVAL
AXSOME THERAPEUTICS - ENTERS SETTLEMENT AGREEMENT WITH FIRST-TO-FILE GENERIC APPLICANT FOR SUNOSI
Source text: ID:nGNX7xGqyF
Further company coverage: AXSM.O
((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Axsome Therapeutics
See all newsUS RESEARCH ROUNDUP-Bright Minds Biosciences, Marvell Technology, Oracle Corporation
Axsome Therapeutics Q3 revenue rises on Auvelity and Sunosi
US RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Axsome Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Axsome Therapeutics Q2 revenue rises on AUVELITY growth